Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Processa Pharmaceuticals is actively participating in the 44th Annual J.P. Morgan Healthcare Conference to discuss its clinical pipeline and engage with investors and potential partners [1][2]. Group 1: Company Overview - Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer (NGC) therapies with improved safety and efficacy [6]. - The company's NGC drugs are modifications of existing FDA-approved oncology therapies aimed at enhancing the metabolism and distribution of these drugs while preserving their cancer-killing mechanisms [6]. Group 2: Clinical Pipeline - The ongoing Phase 2 study is evaluating NGC-Cap in patients with advanced or metastatic breast cancer, with preliminary data indicating that NGC-Cap increases exposure to capecitabine's cancer-killing metabolites while maintaining a safety profile similar to standard capecitabine monotherapy [3][5]. - A formal interim analysis from the first 20 patients enrolled in the Phase 2 study is expected to be completed in early 2026 [3]. Group 3: Strategic Engagement - George Ng, CEO, and Patrick Lin, Chief Business & Strategy Officer, will be available for one-on-one meetings with investors during the conference to discuss the company's clinical pipeline [2][4].